Launch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are uninsured and underinsured and whose out-of-pocket costs exceed Brenzavvy‘s cash ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback